Synergy between the Mos/mitogen-activated protein kinase pathway and loss of p53 function in transformation and chromosome instability

Molecular and Cellular Biology

Volumn 17, Issue 1, 1997, Pages 506-518

  Fukasawa, Kenji ^a   Vande Woude, George F ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN P53;

ANIMAL CELL; ARTICLE; CELL CYCLE G1 PHASE; CELL TRANSFORMATION; CHROMOSOME TRANSLOCATION; CYTOKINESIS; ENZYME ACTIVATION; FIBROBLAST; MITOGENICITY; MITOSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN STABILITY; SPINDLE CELL; TUMOR SUPPRESSOR GENE;

ANIMALIA;

EID: 0031035639     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.17.1.506     Document Type: Article

References (100)

1. Agarwal, M. L., A. Agarwal, W. R. Taylor, and G. R. Stark. 1995. p53 controls both the G2/M and the G1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts. Proc. Natl. Acad. Sci. USA 92:8493-8497.
2. Ahn, N. G., J. E. Weiel, C. P. Chan, and E. G. Krebs. 1990. Identification of multiple epidermal growth factor-stimulated protein serine/threonine kinases from Swiss 3T3 cells. J. Biol. Chem. 265:11487-11494.
3. Alessi, D. R., Y. Saito, D. G. Campbell, P. Cohen, G. Sithanandam, U. Rapp, A. Ashworth, C. J. Marshall, and S. Cowley. 1994. Identification of the sites in MAP kinase kinase-1 phosphorylated by p74raf-1. EMBO J. 13:1610-1619.
4. Alvarez, E., I. C. Northwood, F. A. Gonzalez, D. Latour, A. Seth, C. Abate, T. Curran, and R. J. Davis. 1991. Pro-Leu-Ser/Thr-Pro is a consensus primary sequence for substrate protein phosphorylation: characterization of the phosphorylation of c-myc and c-jun proteins by an epidermal growth factor receptor threonine 669 protein kinase. J. Biol. Chem. 266:15277-15285.
5. Baker, S. J., S. Markowitz, E. R. Fearon, J. K. Willson, and B. Vogelstein. 1990. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 249:912-915.
6. Ball, J., J. A. McCarter, and S. M. Sunderland. 1973. Evidence for helper independent murine sarcoma virus. I. Segregation of replication-defective and transformation-defective viruses. Virology 56:268-284.
7. Ben-David, Y., and A. Bernstein. 1991. Friend virus-induced erythroleukemia and the multistage nature of cancer. Cell 66:831-834.
8. Blair, D. G., W. McClements, M. Oskarsson, P. Fischinger, and G. F. Vande Woude. 1980. Biological activity of cloned Moloney sarcoma virus DNA: terminally redundant sequences may enhance transformation efficiency. Proc. Natl. Acad. Sci. USA 77:3504-3508.
9. Cai, H., P. Erhardt, J. Troppmair, M. T. Diaz-Meco, G. Sithanandam, U. R. Rapp, J. Moscat, and G. M. Cooper. 1993. Hydrolysis of phosphatidylcholine couples Ras to activation of Raf protein kinase during mitogenic signal transduction. Mol. Cell. Biol. 13:7645-7651.
10. Carder, P., A. H. Wyllie, C. A. Purdie, R. G. Morris, S. White, J. Piris, and C. C. Bird. 1993. Stabilised p53 facilitates aneuploid clonal divergence in colorectal cancer. Oncogenc 5:1397-1401.
11. Bouffler, S. D., C. J. Kemp, A. Balmain, and R. Cox. 1995. Spontaneous and ionizing radiation-induced chromosomal abnormalities in p53-deficient mice. Cancer Res. 55:3883-3889.
12. Chen, P.-L., Y. M. Chen, R. Bookstein, and W.-H. Lee. 1990. Genetic mechanisms of tumor suppression by the human p53 gene. Science 250:1576-1580.
13. Choi, T., S. Rulong, J. Resau, K. Fukasawa, W. Matten, R. Kuriyama, S. Mansour, N. Ahn, and G. F. Vande Woude. 1996. Mos/MAPK can induce early meiotic phenotypes in the absence of MPF: a novel system for analyzing spindle formation during meiosis I. Proc. Natl. Acad. Sci. USA 93:4730-4735.
14. Choi, T., K. Fukasawa, R. Zhou, L. Tessarollo, K. Borror, J. Resau, and G. F. Vande Woude. 1996. The Mos/MAPK pathway regulates the size and degradation of the first polar body in maturing mouse oocytes. Proc. Natl. Acad. Sci. USA 93:7032-7035.
15. Cowley, S., H. Paterson, P. Kemp, and C. J. Marshall. 1994. Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells. Cell 77:841-852.
16. Cross, S. M., C. A. Sanchez, C. A. Morgan, M. K. Schimke, S. Ramel, R. L. Idzerda, W. H. Raskind, and B. J. Reid. 1995. A p53-dependent mouse spindle checkpoint. Science 267:1353-1356.
17. Denko, N. C., A. J. Giaccia, J. R. Stringer, and P. J. Stambrook. 1994. The human Ha-ras oncogene induces genomic instability in murine fibroblasts within one cell cycle. Proc. Natl. Acad. Sci. USA 91:5124-5128.
18. Dent, P., W. Haser, T. A. Haystead, L. A. Vincent, T. M. Roberts, and T. W. Sturgill. 1992. Activation of mitogen-activated protein kinase by v-Raf in NIH/3T3 cells and in vitro. Science 257:1404-1407.
19. de Vries, J. E., F. H. Kornips, P. Marx, F. T. Bosman, J. P. Geraedts, and J. ten Kate. 1993. Transfected c-Ha-ras oncogene enhances karyotypic instability and integrates predominantly in aberrant chromosomes. Cancer Genet. Cytogenet. 67:35-43.
20. Diller, L., J. Kassel, C. E. Nelson, M. A. Gryka, G. Litwak, M. Gebhardt, B. Bressac, M. Ozturk, S. J. Baker, B. Vogelstein, and S. H. Friend. 1990. p53 functions as a cell cycle control protein in osteosarcomas. Mol. Cell. Biol. 10:5772-5781.
21. Donehower, L. A., L. A. Godley, C. M. Aldaz, R. Pyle, Y.-P. Shi, D. Pinkel, J. Gray, A. Bradley, D. Medina, and H. E. Varmus. 1995. Deficiency of p53 accelerates mammary tumorigenesis in Wnt-1 transgenic mice and promotes chromosomal instability. Genes Dev. 9:882-895.
22. Donehower, L. A., M. Harvey, B. L. Slagle, M. J. McArthur, C. A. Montgomery, Jr., J. S. Butel, and A. Bradley. 1992. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature (London) 356:215-221.
23. Eliyahu, D., D. Michalovitz, S. Eliyahu, O. Pinhasi-Kimhi, and M. Oren. 1989. Wild-type p53 can inhibit oncogene-mediated focus formation. Proc. Natl. Acad. Sci. USA 86:8763-8767.
24. Erikson, R. L. 1991. Structure, expression and regulation of protein kinases involved in the phosphorylation of ribosomal protein S6. J. Biol. Chem. 266:6007-6010.
25. cde2 and a microtubule-associated protein kinase homolog in Xenopus oocytes and eggs. Mol. Cell. Biol. 11:1965-1971.
26. Finlay, C. A., P. W. Hinds, and A. J. Levine. 1989. The p53 protooncogene can act as a suppressor of transformation. Cell 57:1083-1093.
27. Franza, B. R., Jr., K. Maruyama, J. I. Garrels, and H. E. Ruley. 1986. In vitro establishment is not a sufficient prerequisite for transformation by activated ras oncogenes. Cell 44:409-418.
28. Fukasawa, K., T. Choi, R. Kuriyama, S. Rulong, and G. F. Vande Woude. 1996. Abnormal centrosome amplification in the absence of p53. Science 271:1744-1747.
29. Fukasawa, K., and G. F. Vande Woude. 1995. Mos overexpression in Swiss 3T3 cells induces meiotic-like alterations of the mitotic spindle. Proc. Natl. Acad. Sci. USA 92:3430-3434.
30. Fukasawa, K., S. Rulong, J. Resau, P. Pinto da Silva, and G. F. Vande Woude. 1995. Overexpression of mos oncogene product in Swiss 3T3 cells induces apoptosis preferentially during S-phase. Oncogene 10:1-8.
31. Fukasawa, K., M. S. Murakami, D. G. Blair, R. Kuriyama, T. Hunt, P. Fischinger, and G. F. Vande Woude. 1994. Similarities between somatic cells overexpressing the mos oncogene and oocytes during meiotic interphase. Cell Growth Differ. 5:1093-1103.
32. Fukasawa, K., G. Sakoulas, R. E. Pollack, and S. Chen. 1991. Excess wildtype p53 blocks initiation and maintenance of simian virus 40 transformation. Mol. Cell. Biol. 11:3472-3483.
33. Fukasawa, K. Unpublished observation.
34. Gallego, C., S. K. Gupta, L. E. Heasley, N. X. Qian, and G. L. Johnson. 1992. Mitogen-activated protein kinase activation resulting from selective oncogene expression in NIH 3T3 and rat 1a cells. Proc. Natl. Acad. Sci. USA 89:7355-7359.
35. Gamble, J., and J. Milner. 1988. Evidence that immunological variants of p53 represent alternative protein conformations. Virology 162:452-458.
36. Gannon, J. V., R. Greaves, R. Iggo, and D. P. Lane. 1990. Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J. 9:1595-1602.
37. Gille, H., A. D. Sharrocks, and P. E. Shaw. 1992. Phosphorylation of transcription factor p62 TCF by MAP kinase stimulates ternary complex formation at c-fos promoter. Nature (London) 358:414-417.
38. Gotoh, Y., E. Nishida, S. Matsuda, N. Shiina, H. Kosako, K. Shiokawa, T. Akiyama, K. Ohta, and H. Sakai. 1991. In vitro effects on microtubule dynamics of purified Xenopus M-phase-activated MAP kinase. Nature (London) 349:251-254.
39. Graham, F. L., and A. J. van der Eb. 1973. A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology 52:456-467.
40. Guillouf, C., F. Rosselli, K. Krishnaraju, E. Moustacchi, B. Huffman, and D. A. Liebermann. 1995. p53 involvement in control of G2 exit of the cell cycle: role in DNA damage-induced apoptosis. Oncogene 10:2263-2270.
41. Gupta, S. K., C. Gallego, G. L. Johnson, and L. E. Heasley. 1992. MAP kinase is constitutively activated in gip2 and src transformed Rat 1a fibroblasts. J. Biol. Chem. 267:7987-7990.
42. Harvey, M., H. Vogel, D. Morris, A. Bradley, A. Bernstein, and L. A. Donehower. 1995. A mutant p53 transgene accelerates tumour development in heterozygous but not nullizygous p53-deficient mice. Nat. Genet. 9:305-311.
43. Harvey, M., A. T. Sands, R. S. Weiss, M. E. Hegi, R. W. Wiseman, P. Pantazis, B. C. Giovanello, M. A. Tainsky, A. Bradley, and L. A. Donehower. 1993. In vitro growth characteristics of embryo fibroblasts isolated from p53 deficient mice. Oncogene 8:2457-2467.
44. Hicks, G. G., S. E. Egan, A. H. Greenberg, and M. Mowat. 1991. Mutant p53 tumor suppressor alleles release ras-induced cell cycle growth arrest. Mol. Cell. Biol. 11:1344-1352.
45. Hallstein, M., D. Sidransky, B. Vogelstein, and C. C. Harris. 1991. p53 mutations in human cancers. Science 253:49-53.
46. Howe, L. R., S. J. Leevers, N. Gomez, S. Nakielny, P. Cohen, and C. J. Marshall. 1992. Activation of MAP kinase pathway by the protein kinase raf. Cell 71:335-342.
47. Iggo, R., K. Gatter, J. Bartek, D. Lane, and A. L. Harris. 1990. Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 335:675-679.
48. Kastan, M. B., Q. Zhan, W. S. el-Deiry, F. Carrier, T. Jacks, W. V. Walsh, B. S. Plunkett, B. Vogelstein, and A. J. Fornace, Jr. 1992. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxiatelangiectasia. Cell 71:587-597.
49. Kastan, M. B., O. Onyekwere, D. Sidransky, B. Vogelstein, and R. W. Craig. 1991. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 51:6304-6311.
50. Kastan, M. B., C. E. Canman, and C. J. Leonard. 1995. P53. cell cycle control and apoptosis: implications for cancer. Cancer Metastasis Rev. 14:3-15.
51. Kerr, J. F. R. 1971. Shrinkage necrosis: a distinct mode of cellular death. J. Pathol. 105:13-20.
52. Kuerbitz, S. J., B. S. Plunkett, W. V. Walsh, and M. B. Kastan. 1992. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc. Natl. Acad. Sci. USA 89:7491-7495.
53. Kyriakis, J. M., H. App, X.-F. Zhang, P. Banerjee, D. L. Brautigan, U. R. Rapp, and J. Avruch. 1992. Raf-1 activates MAP kinase-kinase. Nature (London) 358:417-421.
54. Lavigueur, A., V. Maltby, D. Mock, J. Rossant, T. Pawson, and A. Bernstein. 1989. High incidence of lung, bone, and lymphoid tumors in transgenic mice overexpressing mutant alleles of the p53 oncogene. Mol. Cell. Biol. 9:3982-3991.
55. Lee, J. M., and A. Bernstein. 1993. p53 mutations increase resistance to ionizing radiation. Proc. Natl. Acad. Sci. USA 90:5742-5746.
56. Lee, J. M., J. L. Abrahamson, R. Kandel, L. A. Donehower, and A. Bernstein. 1994. Susceptibility to radiation-carcinogenesis and accumulation of chromosomal breakage in p53 deficient mice. Oncogene 9:3731-3736.
57. ras oncoprotein. EMBO J. 11:569-574.
58. Leevers, S. J., H. F. Paterson, and C. J. Marshall. 1994. Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane. Nature (London) 369:411-414.
59. Lin, H.-J., V. Eviner, G. C. Prendergast, and E. White. 1995. Activated H-ras rescues E1A-induced apoptosis and cooperates with E1A to overcome p53-dependent growth arrest. Mol. Cell. Biol. 15:4536-4544.
60. Livingstone, L. R., A. White, J. Sprouse, E. Livanos, T. Jacks, and T. D. Tlsty. 1992. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 70:923-935.
61. Lowe, S. W., H. E. Ruley, T. Jacks, and D. E. Housman. 1993. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 74:957-967.
62. Malkin, D., F. P. Li, L. C. Strong, J. F. Fraumeni, Jr., C. E. Nelson, D. H. Kim, J. Kassel, M. A. Gryka, F. Z. Bischoff, M. A. Tainsky, and S. H. Friend. 1990. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250:1233-1238.
63. Mansour, S. J., W. T. Matten, A. S. Hermann, J. M. Candia, S. Rong, K. Fukasawa, G. F. Vande Woude, and N. G. Ahn. 1994. Transformation of mammalian cells by constitutively active MAP kinase kinase. Science 265: 966-970.
64. Marais, R., J. Wynne, and R. Treisman. 1993. The SRF accessory protein Elk-1 contains a growth factor-regulated transcriptional activation domain. Cell 73:381-393.
65. Martinez, J., I. Georgoff, J. Martinez, and A. J. Levine. 1991. Cellular localization and cell cycle regulation by a temperature-sensitive p53 protein. Genes Dev. 5:151-159.
66. Mercer, W. E., M. T. Shields, M. Amin, G. J. Sauve, E. Appella, J. W. Romano, and S. J. Ullrich. 1990. Negative growth regulation in a glioblastoma tumor cell line that conditionally expresses human wild-type p53. Proc. Natl. Acad. Sci. USA 87:6166-6170.
67. Michalovitz, D., O. Halevy, and M. Oren. 1990. Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53. Cell 62:671-680.
68. Mowat, M., A. Cheng, N. Kimura, A. Bernstein, and S. Benchimol. 1985. Rearrangements of the cellular p53 gene in erythroleukaemic cells transformed by Friend virus. Nature (London) 314:633-636.
69. Nebreda, A. R., C. Hill, N. Gomez, P. Cohen, and T. Hunt. 1993. The protein kinase mos activates MAP kinase kinase in vitro and stimulates the MAP kinase pathway in mammalian somatic cells in vivo. FEBS Lett. 333:183-187.
70. Nebreda, A. R., and T. Hunt. 1993. The c-mos proto-oncogene protein kinase turns on and maintains the activity of MAP kinase, but not MPF, in cell-free extracts of Xenopus oocytes and eggs. EMBO J. 12:1979-1986.
71. Okazaki, K., and N. Sagata. 1995. MAP kinase activation is essential for oncogenic transformation of NIH3T3 cells by Mos. Oncogene 10:1149-1157.
72. 2 checkpoint in rodent cells. Mol. Cell. Biol. 15:3722-3730.
73. Papkoff, J., I. M. Verma, and T. Hunter. 1982. Detection of a transforming gene product in cells transformed by Moloney murine sarcoma virus. Cell 29:417-426.
74. Payne, D. M., A. J. Rossomando, P. Martino, A. K. Erickson, J.-H. Her, J. Shabanowitz, D. F. Hunt, M. J. Weber, and T. W. Sturgill. 1991. Identification of the regulatory phosphorylation sites in pp42/mitogen-activated protein kinase (MAP kinase). EMBO J. 10:885-892.
75. Phelps, W. C., C. L. Yee, K. Münger, and P. M. Howley. 1989. The human papillomavirus type 16 E7 gene encodes transactivation and transformation functions similar to those of adenovirus E1A. Cell 53:539-547.
76. Pomerance, M., F. Schweighoffer, B. Tocque, and M. Pierre. 1992. Stimulation of milogen-activated protein kinase by oncogenic Ras p21 in Xenopus oocytes. Requirement for Ras p21-GTPase-activating protein interaction. J. Biol. Chem. 267:16155-16160.
77. Posada, J., N. Yew, N. G. Ahn, G. F. Vande Woude, and J. A. Cooper. 1993. Mos stimulates MAP kinase in Xenopus oocytes and activates a MAP kinase kinase in vitro. Mol. Cell. Biol. 13:2546-2553.
78. Pulverer, B. J., J. M. Kyriakis, J. Avruch, E. Nikolakaki, and J. R. Woodgett. 1991. Phosphorylation of c-jun mediated by MAP kinases. Nature (London) 353:670-674.
79. Resing, K. A., S. J. Mansour, A. S. Hermann, R. S. Johnson, J. M. Candia, K. Fukasawa, G. F. Vande Woude, and N. G. Ahn. 1995. Determination of v-Mos-catalyzed phosphorylation sites and autophosphorylation sites on MAP kinase kinase by ESI/MS. Biochemistry 34:2610-2620.
80. Robbins, D. J., M. Cheng, E. Zhen, C. A. Vanderbilt, L. A. Feig, and M. H. Cobb. 1992. Evidence for a Ras-dependent extracellular signal-regulated protein kinase (ERK) cascade. Proc. Natl. Acad. Sci. USA 89:6924-6928.
81. Schaefer, D. I., E. M. Livanos, A. E. White, and T. D. Tlsty. 1993. Multiple mechanisms of N-(phosphonoacetyl)-L-aspartate drug resistance in SV40-infected precrisis human fibroblasts. Cancer Res. 53:4946-4951.
82. 2-terminal domain of c-Myc increases transactivation of gene expression. J. Biol. Chem. 266:23521-23524.
83. Shibuya, E. K., A. J. Polverino, E. Chang, M. Wigler, and J. V. Ruderman. 1992. Oncogenic ras triggers the activation of 42-kDa mitogen-activated protein kinase in extracts of quiescent Xenopus oocytes. Proc. Natl. Acad. Sci. USA 89:9831-9835.
84. Shibuya, E. K., and J. U. Ruderman. 1993. Mos induces the in vitro activation of mitogen-activated protein kinases in lysates of frog oocytes and mammalian somatic cells. Mol. Biol. Cell 4:781-790.
85. Steffen, M., U. Scherdin, I. Vértes, W. Boecker, M. Dietel, and F. Hölzel. 1992. Karyotype instability and altered differentiation of rat sarcoma cells after retroviral infection. Genes Chromosomes Cancer 4:46-57.
86. Stokoe, D., S. G. Macdonald, K. Cadwallader, M. Symons, and J. F. Hancock. 1994. Activation of Raf as a result of recruitment to the plasma membrane. Science 264:1463-1467.
87. Storey, A., D. Pim, A. Murray, K. Osborn, L. Banks, and L. Crawford. 1988. Comparison of the in vitro transforming activities of human papillomavirus types. EMBO J. 7:1815-1820.
88. Sturgill, T. W., L. B. Ray, E. Erikson, and J. L. Mailer. 1988. Insulinstimulated MAP-2 kinase phosphorylates and activates ribosomal protein S6 kinase II. Nature (London) 334:715-718.
89. Thomas, S. M., M. DeMarco, G. D'Arcangelo, S. Halegoua, and J. S. Brugge. 1992. Ras is essential for nerve growth factor- and phorbol ester-induced tyrosine phosphorylation of MAP kinases. Cell 68:1031-1040.
90. Verlhac, M.-H., H. de Pennart, B. Maro, M. H. Cobb, and H. J. Clarke. 1993. MAP kinase becomes stably activated at metaphase and is associated with microtubule-organizing centers during meiotic maturation of mouse oocytes. Dev. Biol. 158:330-340.
91. Verlhac, M.-H., J. Z. Kubiak, M. Weber, G. Géraud, W. H. Colledge, M. J. Evans, and B. Maro. 1996. Mos is required for MAP kinase activation and is involved in microtubule organization during meiotic maturation in the mouse. Development 122:815-822.
92. Wahl, A. F., K. L. Donaldson, C. Fairchild, F. Y. Lee, S. A. Foster, G. W. Demers, and D. A. Galloway. 1996. Loss of normal p53 function confers sensitization to taxol by increasing G2/M arrest and apoptosis. Nat. Med. 2:72-79.
93. Wang, H.-C., and R. L. Erikson. 1992. Activation of protein serine-threonine kinases p42, p63, and p87 in Rous sarcoma virus-transformed cells: signal transduction/transformation dependent MBP kinases. Mol. Biol. Cell 3:1329-1337.
94. Weiss, R., N. Teich, H. Varmus, and J. Coffin (ed.). 1985. RNA tumor viruses. Molecular biology of tumor viruses, 2nd ed. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
95. Williams, B. O., L. Remington, D. M. Albert, S. Mukai, R. T. Bronson, and T. Jacks. 1994. Cooperative tumorigenic effects of germline mutations in Rb and p53. Nat. Genet. 7:480-484.
96. Wood, K. W., C. Sarnecki, T. M. Roberts, and J. Blenis. 1992. ras mediates nerve growth factor receptor modulation of three signal-transducing protein kinases: MAP kinase, Raf-1, and RSK. Cell 68:1041-1050.
97. Wyllie, A. H. 1980. Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation. Nature (London) 284:555-556.
98. Yew, N., M. Strobel, and G. F. Vande Woude. 1993. Mos and the cell cycle: the molecular basis of the transformed phenotype. Curr. Opin. Genet. Dev. 3:19-25.
99. Yewdell, J. W., J. V. Gannon, and D. P. Lane. 1986. Monoclonal antibody analysis of p53 expression in normal and transformed cells. J. Virol. 59:444-452.
100. Yin, Y., M. A. Tainsky, F. Z. Bischoff, L. C. Strong, and G. M. Wahl. 1992. Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell 70:937-948.